P/B
1,8
HUTCHMED
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
$2.3B
Market Cap • 9/10/2026
2000
(26 years)
Founded
2016
(10 years ago)
IPO
NASDAQ
Listing Exchange
Hong Kong SAR China
Country
Valuation
P/S
4,2
P/EBITDA
—
P/OCF
111,5
P/FCF
229,2
P/E
131,2
BVPS
7,2
EPS
0,1
Market Cap
Market Cap
2,3B
EV
1B
EV/Revenue
1,8
EV/EBITDA
-49,4
EV/EBIT
-29,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-362,7M
Profitability
Gross Margin
41,6%
EBITDA Margin
—
EBIT Margin
—
Net Margin
5%
D&A/EBITDA
0%
R&D/Revenue
28,2%
Capex/Revenue
1,9%
Capex/D&A
73,7%
Capex/OCF
51,4%
SBC/OCF
53,8%
% PPE
5,4%
% Goodwill
0%
ROE
2,2%
ROIC
—
Growth
CAGR Revenue 5Y
14,5%
CAGR Op. Income 5Y
-33,2%
Leverage
N.D./EBITDA
62,4
Debt/Equity
0%
Current Ratio
5,6
Quick Ratio
5,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!